Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 267

1.

Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.

Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S.

Cancer. 2008 Jul 15;113(2):286-92. doi: 10.1002/cncr.23575.

PMID:
18484590
[PubMed - indexed for MEDLINE]
Free Article
2.

Active surveillance for the management of prostate cancer in a contemporary cohort.

Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.

Cancer. 2008 Jun 15;112(12):2664-70. doi: 10.1002/cncr.23502.

PMID:
18433013
[PubMed - indexed for MEDLINE]
Free Article
3.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
[PubMed - indexed for MEDLINE]
4.

[The significance of rebiopsy in the diagnosis of prostate cancer].

Braun KP, Brookman-Amissah S, May M, Grassmel Y, Heintze C, Hoschke B, Braun V.

Urologe A. 2009 Feb;48(2):163-9. doi: 10.1007/s00120-008-1860-9. German.

PMID:
18797836
[PubMed - indexed for MEDLINE]
5.

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.

Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.

BJU Int. 2008 Jan;101(2):165-9. Epub 2007 Sep 10.

PMID:
17850361
[PubMed - indexed for MEDLINE]
6.

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G.

J Urol. 2002 Apr;167(4):1664-9.

PMID:
11912384
[PubMed - indexed for MEDLINE]
7.

An analysis of men with clinically localized prostate cancer who deferred definitive therapy.

Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT.

J Urol. 2004 Apr;171(4):1520-4.

PMID:
15017211
[PubMed - indexed for MEDLINE]
8.

Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.

Abouassaly R, Lane BR, Jones JS.

Urology. 2008 Apr;71(4):573-7. doi: 10.1016/j.urology.2007.11.094.

PMID:
18387385
[PubMed - indexed for MEDLINE]
9.

Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.

Scattoni V, Roscigno M, Freschi M, Dehò F, Raber M, Briganti A, Fantini G, Nava L, Montorsi F, Rigatti P.

Arch Ital Urol Androl. 2005 Mar;77(1):31-6.

PMID:
15906787
[PubMed - indexed for MEDLINE]
10.

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

Klotz L.

Urol Oncol. 2006 Jan-Feb;24(1):46-50.

PMID:
16414494
[PubMed - indexed for MEDLINE]
11.

Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.

Motamedinia P, RiChard JL, McKiernan JM, DeCastro GJ, Benson MC.

Urology. 2012 Nov;80(5):1070-4. doi: 10.1016/j.urology.2012.07.049.

PMID:
23107398
[PubMed - indexed for MEDLINE]
12.

Patterns of local failure following prostate brachytherapy.

Stone NN, Stock RG, White I, Unger P.

J Urol. 2007 May;177(5):1759-63; duscussion 1763-4.

PMID:
17437808
[PubMed - indexed for MEDLINE]
13.

Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.

Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A.

Eur Urol. 2009 Mar;55(3):600-6. doi: 10.1016/j.eururo.2008.06.043. Epub 2008 Jun 23.

PMID:
18597923
[PubMed - indexed for MEDLINE]
14.

Clinical significance of repeat sextant biopsies in prostate cancer patients.

Stroumbakis N, Cookson MS, Reuter VE, Fair WR.

Urology. 1997 Mar;49(3A Suppl):113-8.

PMID:
9123730
[PubMed - indexed for MEDLINE]
15.

Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.

King AC, Livermore A, Laurila TA, Huang W, Jarrard DF.

Urol Oncol. 2013 Aug;31(6):739-43. doi: 10.1016/j.urolonc.2011.06.011. Epub 2011 Aug 3.

PMID:
21816639
[PubMed - indexed for MEDLINE]
16.

Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.

Gallo F, Chiono L, Gastaldi E, Venturino E, Giberti C.

Urology. 2008 Sep;72(3):628-32. doi: 10.1016/j.urology.2007.11.115. Epub 2008 Feb 15.

PMID:
18279918
[PubMed - indexed for MEDLINE]
17.

Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.

PMID:
22564446
[PubMed - indexed for MEDLINE]
18.

A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B.

J Urol. 2009 Apr;181(4):1635-41; discussion 1641. doi: 10.1016/j.juro.2008.11.109. Epub 2009 Feb 23.

PMID:
19233410
[PubMed - indexed for MEDLINE]
19.

Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.

Boccon-Gibod LM, de Longchamps NB, Toublanc M, Boccon-Gibod LA, Ravery V.

J Urol. 2006 Sep;176(3):961-3; discussion 963-4.

PMID:
16890668
[PubMed - indexed for MEDLINE]
20.

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer.

Stephenson AJ, Aprikian AG, Souhami L, Behlouli H, Jacobson AI, Bégin LR, Tanguay S.

Urology. 2002 May;59(5):652-6.

PMID:
11992834
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk